For years, the healthcare industry has been a cornerstone of the economy, offering resilience in both stable and uncertain ...

Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...

Here are 10 of the best health care stocks to buy in 2024, according to CFRA analysts: *As of Sept. 10 close. Based on ...

AbbVie ABBV stock has gained 19.4% in the past three months compared with an increase of 8.1% for the industry. The stock has ...

With the Federal Reserve potentially cutting interest rates for the first time in over four years, uncertainty looms in the ...

In 2022, the global oncology market was valued at approximately $203.42 billion and is expected to reach over $470.61 billion ...

We recently published a list of 10 Best Big-Name Stocks to Buy Right Now According to Short Sellers. In this article, we are ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on AbbVie (ABBV – Research Report) and keeping the price target at ...

AbbVie(NYSE:ABBV) is navigating a period of significant developments, including a robust 4% increase in operational sales and ...

The first notable agency action in 2024 is the FTC’s Second Request in Novo Holding’s proposed $16.5 billion acquisition of Catalent, a life sciences contract manufacturer. 1 The agency’s interest in ...